Convatec raises medium term revenue growth targets following strong annual profit
Convatec raised its revenue growth targets after reporting a 12 percent rise in annual profit. Strong demand for chronic care products supported the results.
Insights:
ConvaTec Group Plc announced on February 24, 2026, that it has raised its medium-term organic revenue growth target to 6%–8%, marking an increase from the previous 5%–7% range. This material update to the company's forward expectations was issued alongside annual results showing that annual adjusted operating profit rose by more than 12%. The company cited a strengthening medical product pipeline as a primary factor in the revised guidance.
The United Kingdom 
GB based company is currently executing a strategic pivot to become a pure-play chronic-care business. This transition is central to the updated revenue performance expectations and the company's long-term strategy. As part of this focus, the company is leveraging its chronic-care portfolio to drive growth across its global operations.
GB based company is currently executing a strategic pivot to become a pure-play chronic-care business. This transition is central to the updated revenue performance expectations and the company's long-term strategy. As part of this focus, the company is leveraging its chronic-care portfolio to drive growth across its global operations.
